We also found no impact of EGFR status on progression-free survival, indicating that EGFR overexpression is not associated with more aggressive tumor biology or with resistance to chemotherapy in gastric and GE junction adenocarcinoma. Here, EGFR is linked to gastroesophageal junction adenocarcinoma.